US$ 21.60
tirzepatide costs New Pricing, Access to Available Through Self-Pay Options Tirzepatide could raise costs more
Description
Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending

Both create opportunity for dietary supplement retailers.

Jan 12 (Reuters) - Oral weight-loss drugs could make up a third or more of the overall GLP-1 market by 2030, a larger percentage than the company originally anticipated, a Novo Nordisk executive said

GLP-1 receptor agonist therapy no longer requires insurance coverage or expensive clinic visits

Merck had other China deals in the last few months (LaNova Medicines and Curon Biopharmaceutical), but all deals are either early-stage (ongoing Phase 1) or pre-clinical (Hansoh)

Explore top weight loss programs featuring personalized plans and innovative GLP-1 medications like Ozempic and Wegovy
